Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer

被引：0
|
作者：
Lenz, H-J. [1 ]
Park, H. [2 ]
Shah, M. A. [3 ]
Berlin, J. D. [4 ]
Bruetman, D. [5 ]
Chaves, J. [6 ]
Gordon, M. [7 ]
Patel, R. [8 ]
Starodub, A. [9 ]
Liu, J. [10 ]
Brachmann, C. Baker [11 ]
Bhargava, P. [12 ]
Wainberg, Z. A. [13 ]
Bendell, J. [14 ]
机构：
[1] Univ Southern Calif, Keck Sch Med, Med Oncol, Los Angeles, CA USA
[2] Washington Univ, Sch Med, Oncol, St Louis, MO USA
[3] Weill Cornell Med, New York Presbyterian Hosp, Dept Med, New York, NY USA
[4] Vanderbilt Ingram Canc Ctr, Med, Nashville, TN USA
[5] Goshen Ctr Canc Care, Dept Med, Goshen, IN USA
[6] Northwest Med Specialties PLLC, Dept Med, Tacoma, WA USA
[7] HonorHlth Res Inst, Med Oncol, Scottsdale, AZ USA
[8] Comprehens Blood & Canc Ctr, Dept Med, Bakersfield, CA USA
[9] Indiana Univ Hlth, Goshen Hosp, Dept Med, Goshen, IN USA
[10] Gilead Sci Inc, Dept Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA
[11] Gilead Sci Inc, Dept Biomarkers, 353 Lakeside Dr, Foster City, CA 94404 USA
[12] Gilead Sci Inc, Dept Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[13] Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90024 USA
[14] Sarah Cannon Res Inst, Dept Med, Nashville, TN USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
567P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    R P W Wong
    G D'Haens
    J-Y Douillard
    J Robertson
    A M Stone
    E Van Cutsem
    British Journal of Cancer, 2013, 108 : 493 - 502
  • [2] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    Cunningham, D.
    Wong, R. P. W.
    D'Haens, G.
    Douillard, J-Y
    Robertson, J.
    Stone, A. M.
    Van Cutsem, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 493 - 502
  • [3] Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer
    Hamilton, Erika Paige
    Bessudo, Alberto
    Bruetman, Daniel
    Gordon, Michael S.
    Patel, Ravindranath
    Adewoye, Adeboye H.
    Liu, JieJane
    Starodub, Alexander
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer
    M. Michael
    J. Zalcberg
    P. Gibbs
    L. Lipton
    M. Gouillou
    M. Jefford
    G. McArthur
    M. Copeman
    K. Lynch
    N. C. Tebbutt
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 321 - 330
  • [5] A phase I clinical trial of riluzole in combination with mFOLFOX6 and bevacizumab in treating patients with metastatic colorectal cancer.
    Li, Chunjie
    Noonan, Anne M.
    Hays, John L.
    Roychowdhury, Sameek
    Malalur, Pannaga G.
    Elkhatib, Rifat T.
    Manne, Ashish
    Mittra, Arjun
    Rahman, Shafia
    Phelps, Mitch A.
    Liang, Beiyuan
    Storts, Hadyen
    Khan, Misbah
    Zhang, Evan
    Zheng, Xinru
    Miles, Wayne
    Wang, Jing
    Jin, Ning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 101 - 101
  • [6] MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)
    Schmoll, H.
    Cunningham, D.
    Sobrero, A.
    Karapetis, C.
    Rougier, P.
    Koski, S. L.
    Barker, P.
    Mookerjee, B.
    Robertson, J.
    van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 189
  • [7] A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).
    Uetake, Hiroyuki
    Emi, Yasunori
    Yamanaka, Takeharu
    Muro, Kei
    Oki, Eiji
    Takahashi, Takao
    Nagasaka, Takeshi
    Hatano, Etsuro
    Ojima, Hitoshi
    Manaka, Dai
    Kusumoto, Tetsuya
    Katayose, Yu
    Fujiwara, Toshiyoshi
    Yoshida, Kazuhiro
    Unno, Michiaki
    Hyodo, Ichinosuke
    Tomita, Naohiro
    Sugihara, Kenichi
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] A Phase I/II, Open-label, Randomised Study of BIBF 1120 Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 in Patients with Metastatic Colorectal Cancer
    Van Cutsem, E.
    Prenen, H.
    Guillen-Ponce, C.
    Bennouna, J.
    Di Benedetto, M.
    Bouche, O.
    Staines, H.
    Oum'Hamed, Z.
    Studeny, M.
    Capdevila, J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 8 - 9
  • [9] Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer
    O'Neil, Bert H.
    Cainap, Calin
    Van Cutsem, Eric
    Gorbunova, Vera A.
    Karapetis, Christos Stelios
    Berlin, Jordan
    Goldberg, Richard M.
    Qin, Qin
    Qian, Jiang
    Ricker, Justin L.
    McKee, Mark D.
    Carlson, Dawn M.
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer
    Taroh Satoh
    Kensei Yamaguchi
    Narikazu Boku
    Wataru Okamoto
    Tomotaka Shimamura
    Kentaro Yamazaki
    Xiaojin Shi
    Hideyuki Mishima
    Investigational New Drugs, 2012, 30 : 1511 - 1518
12345